Amgen (AMGN) Receivables (2009 - 2026)

Amgen has reported Receivables for 18 years, with the latest figure at $10.2 billion in Q2 2026.

• On a quarterly basis, Receivables rose 17.54% year-over-year to $10.2 billion in Q2 2026; TTM through Jun 2026 was $10.2 billion, a 17.54% increase from a year earlier, with the FY2025 full-year figure at $9.6 billion, up 31.04% from the prior year.
• Receivables was $10.2 billion for Q2 2026 at Amgen, up from $9.1 billion in the prior quarter.
• The five-year high for Receivables was $10.2 billion in Q2 2026, with the low at $5.1 billion in Q1 2022.
• Average Receivables over 5 years is $7.2 billion, with a median of $7.1 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables fell 6.01% in 2024, then jumped 31.04% in 2025.
• Over 5 years, Receivables stood at $6.3 billion in 2022, then increased by 24.06% to $7.8 billion in 2023, then slipped by 6.01% to $7.3 billion in 2024, then surged by 31.04% to $9.6 billion in 2025, then increased by 6.87% to $10.2 billion in 2026.
• The last three Receivables figures came in at $10.2 billion (Q2 2026), $9.1 billion (Q1 2026), and $9.6 billion (Q4 2025), per Business Quant data.